Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1/2 2 Phase 1 2 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 1 Lung Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 15 Fluorouracil 13 Bevacizumab 13 Leucovorin 10 Capecitabine 8 Folfox protocol 7 Irinotecan 6 IFL protocol 4 Cetuximab 4 Folic Acid 3 Aspirin 3 atezolizumab 2 XELOX 2 Surgical Procedures, Operative 2 Magnetic Resonance Spectroscopy 2 Drug Therapy 2 Chemotherapy, Adjuvant 2 trifluridine tipiracil drug combination 1 trametinib 1 titanium silicide 1 sulindac sulfone 1 spartalizumab 1 sacituzumab govitecan 1 regorafenib 1 raltitrexed 1 pertuzumab 1 irinotecan sucrosofate 1 folfirinox 1 envafolimab 1 dabrafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Colorectal Neoplasms × cediranib × Clear all

NCT00384176 2017-04-14

HORIZON III

AstraZeneca

Phase 2/3 Completed

1,814 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡